Efficacy of non-Hodgkin’s lymphoma cancer vaccine demonstrated in dogs

An experimental vaccine is the first veterinary cancer vaccine of its kind that shows an increase in survival time for dogs with spontaneous non-Hodgkin’s lymphoma. The work shows for the first time the feasibility and therapeutic efficacy of this alternative cell-based vaccine, which could be employed in the treatment of a number of different cancer types . . .

. . . The team recruited dogs that were brought to Penn’s Matthew J. Ryan Veterinary Hospital with newly diagnosed non-Hodgkin’s lymphoma to receive the experimental vaccine following standard induction chemotherapy and confirmation of clinical remission. The goal of the study was to determine whether the cancer vaccine would prevent or prolong time to a relapse, a common scenario in both humans and dogs with NHL.

“We vaccinated dogs, which were in clinical remission following chemotherapy, three times,” Mason said. “We then tracked them over several years to see if the vaccine would prevent relapse and would prolong overall survival.

Read More: ScienceDaily: Dog News Efficacy of non-Hodgkin’s lymphoma vaccine demonstrated in dogs

Like this article?

Share on facebook
Share on Facebook
Share on twitter
Share on Twitter
Share on linkedin
Share on Linkdin
Share on pinterest
Share on Pinterest

Leave a comment

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Scroll to Top